Stem Cell Sciences goes US
Wednesday, 04 March, 2009
Technology company Stem Cell Sciences (SCS) is to be sold to Delaware’s StemCells Inc for close to US$5 million.
SCS, which has a research laboratory in Melbourne and is headquartered in Cambridge in the UK, has an impressive portfolio of IP based around technologies for stem cell research including cell-based assays, gene delivery vehicles, cell media and methodologies.
In a statement, the companies said it was expected that SCS’s 20 full-time staff will be retained if the deal goes ahead. Agreement has already been received from 30 per cent of SCS shareholders.
An EGM to vote on the deal will be held in London on 27 March.
mRNA therapy found to prevent recurrence of melanoma
Merck and Moderna have announced positive topline results from their Phase 3 trial of a...
A high-performance method for CRISPR off-target nomination
A new study provides evidence that can help gene editing developers prioritise biologically...
High doses of fertility drug linked to pregnancy risks
High doses of clomiphene citrate, accumulated over multiple fertility treatment cycles, could...
